Searchable abstracts of presentations at key conferences in endocrinology

ea0090p65 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Gender differences in smoking cessation? Results of a randomized controlled trial of dulaglutide-assisted smoking cessation

Baur Fabienne , David Coynel , Atila Cihan , Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Bathelt Cemile , Christ-Crain Mirjam , Winzeler Bettina

Introduction: Smoking harms women more than men and women seem to be less successful in quitting. Greater concerns about post-cessational weight in women and gender differences in craving and reward processing have been postulated as possible explanations. Our group recently showed that the GLP-1 analogue dulaglutide reduces post-cessational weight gain. We hypothesize that women compared to men might profit more from the weight-lowering effects of dulaglutide in terms of abst...

ea0090p422 | Pituitary and Neuroendocrinology | ECE2023

Effects of a GLP-1 agonist on consumption of alcohol in patients treated for smoking cessation

Sofia Probst Leila , Monnerat Sophie , Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Bathelt Cemile , Christ-Crain Mirjam , Winzeler Bettina

Introduction: Alcohol use disorder AUD causes high socio-economic costs and has a detrimental impact on health globally, being considered a key risk factor for non-communicable diseases. In Switzerland, four substances are currently approved for treatment of AUD, with varying effects. Taking into consideration the complex nature of the disease and the heterogeneity of affect patients, it becomes evident that there is need for new treatment targets. A body of preclinical studie...

ea0013s6biog | Clinical Endocrinology Trust Visiting Professor Lecture | SFEBES2007

Clinical Endocrinology Trust Visiting Professor Lecture

Dunaif Andrea

Andrea Dunaif, Northwestern University, Feinberg School of Medicine, Chicago, United States. AbstractDr Dunaif received her MD from Columbia University College of Physicians and Surgeons, trained in New York and Boston and rose to rank of Associate Professor at the Mount Sinai School of Medicine. Since 1992 Dr Dunaif has held posts at Brigham and Women’s Hospital as Director of Women’s Health and Chief of the...

ea0099p31 | Adrenal and Cardiovascular Endocrinology | ECE2024

Blood pressure changes during smoking cessation on dulaglutide and placebo treatment – a secondary analysis of the randomized, double-blind, placebo-controlled SKIP trial

Julia Beck , Hasenbohler Flavia , Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Jeanloz Nica , Vukajlovic Tanja , Bologna Katja , Bathelt Cemile , Vogt Deborah , Werlen Laura , Christ-Crain Mirjam , Winzeler Bettina

Objective: Smoking is an established major risk for atherosclerosis and cardiovascular mortality. However, the impact of smoking cessation on blood pressure remains controversial. Despite strong evidence linking smoking cessation to reduced cardiovascular risk, conflicting studies suggest potential increases in blood pressure after smoking cessation. Post cessational weight gain may contribute to these confliciting findings. We have recently shown that the glucagon-like peptid...

ea0081p76 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Glucagon-like peptide-1 analogues: a new way to quit smoking? SKIP – a randomised controlled study

Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Jeanloz Nica , Vukajlovic Tanja , Bologna Katja , Steinmetz Michelle , Sailer Clara , Coynel David , Vogt Deborah R , Hemkens Lars G. , Speich Benjamin , Kuhne Jill , Baur Fabienne , Lutz Linda , Bathelt Cemile , Zanchi Davide , Christ-Crain Mirjam , Winzeler Bettina

Background: Cigarette smoking is the leading preventable cause of premature death. Smoking cessation is one of the central goals in medicine, but despite dedicated programs, quit rates remain low due to barriers such as nicotine withdrawal syndrome or post-cessation weight gain. Glucagon-like peptide-1 (GLP-1) analogues reduce energy intake and body weight and seem to modulate addictive behavior. These GLP-1 properties are of major interest in the context of smoking cessation....

ea0049ep889 | Neuroendocrinology | ECE2017

Empagliflozin increases urinary volume output in healthy volunteers with artificial SIADH – a placebo-controlled double blind crossover study

Refardt Julie , Winzeler Bettina , Meienberg Fabian , Vogt Deborah , Christ-Crain Mirjam

Introduction: The Syndrome of inappropriate antidiuresis (SIADH) is the predominant cause of hyponatremia and its therapy options are unsatisfying. SGLT2-inhibitors have become a valuable treatment option for type 2 diabetes by increasing glucose excretion in the urine with concomitant osmotic diuresis. We therefore hypothesized that SGLT2-inhibitors could be a novel treatment option for SIADH.Material and methods: We included 14 healthy volunteers in th...

ea0063s3.2 | Circadian clocks: from pathophysiology to chronomedicine | ECE2019

Fixing the broken clock in adrenal disorders

Isidori Andrea

Context: Glucocorticoids (GC) mediate some of the adverse health-related consequences of circadian misalignment, such occurs in shift workers who have an increased cardio-metabolic, immune and cancer risk. Investigating the effect of circadian cortisol exposure in patients with GC excess and defect is crucial. In a therapeutic perspective large attention has been given to the total daily GC exposure, much less to the timing-of-the-day relative exposure. Clock genes are essenti...

ea0063s15.2 | European Young Endocrine Scientists (EYES) | ECE2019

Investigating glucocorticoid excess as mediators of bone marrow adiposity expansion during caloric restriction

Lovdel Andrea

Background: Bone marrow adipose tissue (BMAT) comprises >10% of total adipose mass in healthy humans and further increases during caloric restriction (CR). However, BMAT function during CR and other conditions remains poorly understood. Circulating glucocorticoids also increase during CR, and glucocorticoid therapy increases BMAT; thus, we hypothesise that glucocorticoid excess mediates BMAT expansion during CR. Many effects of endogenous glucocor...

ea0063s18.2 | Congenital hypogonadotropic hypogonadism: New insights into GnRH Regulation | ECE2019

Flipping the GnRH switch with microRNAs

Messina Andrea

A sparse population of a few hundred primarily hypothalamic neurons forms the hub of a complex neuroglial network that controls reproduction in mammals by secreting the ‘master molecule’, gonadotropin-releasing hormone (GnRH). Both the Kisspeptin input on GnRH neurons and timely changes in GnRH expression are necessary for the onset of puberty. However, the exact molecular mechanisms underlying this process remain elusive. Here, we report that a dramatic inversion in...

ea0041d1.3 | The use of NSAIDs in endocrine cancers: the case of Celecoxib | ECE2016

The use of NSAIDs in endocrine cancers: the case of Celecoxib AGAINST

Sacchetti Andrea

The antitumor properties of non-steroidal anti-inflammatory drugs (NSAIDs), with respect to both cancer prevention and therapy, have raised considerable interest in the last two decades, leading to well consolidated evidences in gastrointestinal cancers, especially colorectal cancer. NSAID action has been proposed to occur through two independent modes: a COX-dependent one, mainly involving the inhibition of COX-2-mediated PGE2 production, and a COX-independent one, mainly inv...